

Jacob J Chabon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8052824/publications.pdf>

Version: 2024-02-01

25
papers

4,804
citations

430754

18
h-index

580701

25
g-index

25
all docs

25
docs citations

25
times ranked

6701
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated digital error suppression for improved detection of circulating tumor DNA. <i>Nature Biotechnology</i> , 2016, 34, 547-555.	9.4	837
2	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , 2017, 7, 1394-1403.	7.7	701
3	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016, 7, 11815.	5.8	520
4	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. <i>Nature Genetics</i> , 2017, 49, 1693-1704.	9.4	423
5	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.	13.7	379
6	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. <i>Science Translational Medicine</i> , 2016, 8, 364ra155.	5.8	348
7	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2845-2853.	0.8	313
8	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	13.5	206
9	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 176-183.	5.7	201
10	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , 2021, 39, 1537-1547.	9.4	151
11	Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. <i>Gastroenterology</i> , 2020, 158, 494-505.e6.	0.6	147
12	A mathematical model of ctDNA shedding predicts tumor detection size. <i>Science Advances</i> , 2020, 6, .	4.7	105
13	<i>KEAP1/NFE2L2</i> Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1826-1841.	7.7	93
14	Molecular profiling of single circulating tumor cells from lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E8379-E8386.	3.3	90
15	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	3.2	74
16	Inferring gene expression from cell-free DNA fragmentation profiles. <i>Nature Biotechnology</i> , 2022, 40, 585-597.	9.4	63
17	Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2018, 24, 2688-2699.	3.2	45
18	Deactivated CRISPR Associated Protein 9 for Minor-Allele Enrichment in Cell-Free DNA. <i>Clinical Chemistry</i> , 2018, 64, 307-316.	1.5	30

#	ARTICLE	IF	CITATIONS
19	Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. <i>Journal of Oncology</i> , 2017, 2017, 1-5.	0.6	20
20	A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2016-2025.	1.9	15
21	Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. <i>Cancer Research</i> , 2022, 82, 2838-2847.	0.4	14
22	Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2015, 126, 114-114.	0.6	10
23	Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 130-130.	0.6	9
24	Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2930-2930.	0.6	8
25	Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 755-757.	0.8	2